Ebbtide Was Created to Target Menstrual Discomfort at the Source
Laura McQuarrie — May 12, 2026 — Lifestyle
References: vellabio & prnewswire
Ebbtide is Vella Bioscience's first vaginal insert, designed to support comfort and ease with a targeted approach to menstrual and pelvic discomfort. Unlike oral medications that work systemically, this suppository delivers active ingredients, like Vella's proprietary cannabidiol precision technology, locally.
"Menstrual and pelvic discomfort are often minimized or normalized, but they shouldn't be," said Dr. Maria Uloko, MD, board-certified urologist, women's sexual health specialist, and member of Vella's Scientific Advisory Board. "Ebbtide is different because it works at the physiological source of cramping and tension. The underlying science—developed by Vella's R&D team—focuses on reducing uterine contractility through a novel combination of CBD and CBDA." In clinical trials, 81% of women reduced or eliminated their use of oral medications while using Ebbtide.
"Menstrual and pelvic discomfort are often minimized or normalized, but they shouldn't be," said Dr. Maria Uloko, MD, board-certified urologist, women's sexual health specialist, and member of Vella's Scientific Advisory Board. "Ebbtide is different because it works at the physiological source of cramping and tension. The underlying science—developed by Vella's R&D team—focuses on reducing uterine contractility through a novel combination of CBD and CBDA." In clinical trials, 81% of women reduced or eliminated their use of oral medications while using Ebbtide.
Trend Themes
-
Localized Biologic Delivery — Targeted vaginal delivery of CBD/CBDA formulations enables higher local bioavailability and reduced systemic exposure, opening pathways for symptom-specific therapeutics.
-
Cannabinoid Precision Therapeutics — Precision-engineered cannabinoid blends tailored to tissue-specific mechanisms reveal potential for regulated, receptor-specific symptom modulation.
-
Women-centric Clinical Validation — Robust trial evidence showing reduced oral medication dependence reframes product development priorities toward female-specific pelvic health solutions.
Industry Implications
-
Women's Health Devices — Device makers could integrate drug-device combination inserts focused on uterine contractility modulation to create new classes of non-oral therapies.
-
Pharmaceutical Formulations — Formulation companies specializing in lipophilic cannabinoid stability and mucosal absorption may unlock novel dosage forms with improved onset and durability.
-
Sexual and Reproductive Wellness Retail — Retailers and DTC brands positioning clinically supported, targeted inserts may shift consumer expectations toward medically validated wellness products.
5.1
Score
Popularity
Activity
Freshness
